Full Title
An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants with Relapsed Platinum Sensitive Ovarian Cancer (PSOC)Purpose
Researchers are doing this study to see how well COM701 immunotherapy works when used as maintenance therapy for ovarian cancer. Maintenance therapy helps keep cancer from growing again after it shrank or stopped growing following earlier treatment.
The people in this study have platinum-sensitive ovarian cancer (PSOC). Their cancer got worse more than 6 months after finishing platinum-based chemotherapy. They are getting or recently finished additional chemotherapy, and their cancer shrank or stopped growing.
COM701 works by blocking proteins that act as brakes on the immune system. Blocking these proteins is like releasing the brakes, so the immune system can target and destroy cancer cells. COM701 is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have PSOC that shrank or stopped growing after additional chemotherapy.
- Have recovered from the serious side effects of other anti-cancer treatments before getting COM701.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Michael Conroy’s office at 646-888-4214.